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ABSTRACT 
Monitoring levels ofpsychopharmacological agents for the purpose of optimising treatment 
is being recommended for increasing number of situations in routine psychiatry practice by some 
western authors. As a result most psychiatrists in developed countries advise drug assays for 
many patients on psychopharmacological treatment. Even in developing countries like India, thera-
peutic drug monitoring (TDM) is being advised more frequently, thus creating a demand for facili-
ties. This paper reviews the need & feasibility of TDM in developing countries focussing on cost 
effectiveness, ethnopharmacological and sociocultural issues. Recommendations are made for 
using TDM in developing countries only in certain specific & selected clinical situation. Cost-effec-
tiveness of stn'ct serum lithium monitoring is discussed from a community health point of view. 
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Therapeutic drug monitoring (TDM) for 
optimising drug treatment in psychiatric 
patients is being recommended more and more 
frequently in developed countries. In a detailed 
review Preskorn et al. (1993) recommended 
drug assay in a wide variety of clinical 
situations, implying a more or less routine use. 
Various indications cited are optimising dosage, 
checking compliance, for differentiating 
between depression and neuroleptic induced 
akinesia, for known cases of toxicity, for 
medico-legal and consumer purposes and for 
ensuring drug wash out to avoid overlap drug 
interaction, among several other situations. In 
developing countries, already more and more 
psychiatrists are resorting to drug assays not 
only for lithium and anticonvulsants, but also 
for antidepressants and neuroleptics. This is 
gradually creating a demand, at least in big cit-
ies, for this sophisticated and costly laboratory 
facility. 
It is submitted that developing countries 
need to assess the need, feasibility and cost 
effectiveness of T.D.M. under different socio-
cultural conditions. This paper examines these 
issues under following headings:-
1. Cost considerations 
2. Availability of TDM 
3. Reliability of laboratories 
4. Interracial differences with bearing on 
TDM 
5. Cultural issues 
6. Need and recommendations for devel-
oping countries 
Cost considerations 
Psychotropic drugs are present in very 
small concentrations in blood and assaying 
them requires sophisticated technology. TDM 
by nature is costly. Cost of a single plasma level 
of tricyclic antidepressant is several times a 
psychiatrist's consultation fee and therefore 
requires strict justification. Total cost of 
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treatment of depression for individual and 
community will go up considerably if TDM is 
used routinely, since depression is the common-
est disorder in psychiatry practice constituting 
over 50% of patients. Cost is daunting even for 
other drugs. 
Cost of single drug assay (figures for India) 
1. Lithium Rs. 150 
2. Carbamazepine Rs. 500 
3. Tricyclic antidepressants Rs. 400 
4. Neuroleptics Rs. 400 
5. Psychiatrist's consultation Rs. 100 
In case of certain drugs like haloperidol 
and carbamazepine, active metabolites may 
need to be measured additionally, and in case 
of decanoate neuroleptic preparations, 
periodical levels need to be done. These 
factors further increase the cost. Cost gets 
further escalated if cost of transport or of spe-
cial containers for sending samples is consid-
ered since facilities fordoing plasma levels are 
few and far between, in most developing 
countries. 
Availability of TDM 
Even if affordable as a routine procedure 
which it is not and even if useful, availability of 
TDM is a serious problem at present in most of 
the developing countries. Taking the example 
of Punjab which is the one of the most 
prosperous state of India, there is not a single 
government or private laboratory capable of 
handling plasma assay for TCA or 
neuroleptics. Serum lithium estimations are 
done in few laboratories, which are attached to 
medical colleges and at some private 
laboratories in big cities. Twelve out of seven-
teen district head quarters do not have 
facilities for lithium estimations; carbamazepine 
drug assays is possible in three out of 
seventeen districts in few private laboratories. 
At a rough estimate, if TDM is advised 
routinely in the present condition of availability, 
each patients or his sample in special 
containers will travel an average of 150 kms 
every time blood level needs to be done. 
Reliability of laboratories 
Even when affordable and available, how 
reliable are the laboratories? 
USA has a Clinical Laboratories Improve-
ment Act of 1972 which states that H\\ clinical 
laboratories should be subject to external 
proficiency testing in addition to internal 
control system and local exchange of standard 
sample. In a survey called American Associa-
tion for Clinical Chemistry TDM Programme, 
which included 80 laboratories, it was reported 
that "result of these surveys to date indicate 
that the analysis of antidepressants is signifi-
cantly less well developed and controlled than 
the analysis of other drugs that are monitored 
for therapeutic purpose. The coefficient of 
variation among the laboratories for TCA was 
in excess of 30%" (American Psychiatric 
Association, 1985). 
In most other countries, where there are 
no such statutory provisions, situation is much 
worse, errors are much higher and are not talked 
about or even known. 
Even if errors in peripheral laboratories 
in other countries pertaining to TCA are taken 
to be around 30% (and they are likely to be 
much higher), the levels lose their relevance 
for crucial dose titration and would be relevant 
only for grossly noncompliant cases or cases 
of acute toxicity. Even if levels are not expected 
to be etched on stone, an error of more than 
10% would render the fine tuning of dose 
titration meaningless. There is a strong need to 
ensure quality control before the profession rec-
ommends TDM, as a routine. 
Inter-racial differences with bearing 
on TDM 
1. Dosage of beta-blockers required for 
treating hypertension in Asians as compared 
to Caucasians (Zhou et al., 1989) are much less, 
cause is difference in sensitivity of 
adrenoceptors (Kalow, 1989). It is a 
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pharmacodynamic and not a pharmacokinetic 
difference. 
2. Both the dosage and therapeutic concentra-
tion of lithium required for treatment and 
prophylaxis of mania have been consistently 
shown to be lower for Asian patients than for 
their Caucasian counterparts. Japanese patients 
required low therapeutic blood levels of 0.4-0.8 
meq/l in contrast to Caucasians who require 0.7-
1.3 meq/l (Stickland et al., 1993). However, no 
pharmacokinetic differences have been 
reported between these two races (Honda and 
Suzuki, 1979). Drug is metabolised in same 
manner and speed. The difference in response 
is because of differences in receptors' 
sensitivity. 
3. Yamashita & Asano (1979) reported that 
doses of imipramine and amitriptyline 
prescribed in Asian countries (70-134mg/day) 
were much lower than in USA and also that 
depressed patients in Asia respond to fairly low 
steady state plasma concentrations of TCAs. 
The clear message from these studies is that 
since therapeutic and probably toxic levels for 
different races are likely to be different. TDM 
studies from West, where most of studies have 
been done, cannot be automatically applied to 
patient populations in East and before indig-
enous reports are available, TDM should not 
be recommended for routine use. 
Cultural considerations 
1. One of the major indications of TDM cited by 
Western authors is to monitor compliance 
(Preskorn et al., 1993). In most Eastern coun-
tries, because of extended families, compliance 
is comparatively less of a problem and even 
when patients are non-compliant, the fact of 
non-compliance is well known to family 
members obviating the need of plasma assay 
to assess compliance. 
2. Another major indication for TDM cited by 
same authors is for medico-legal purposes. 
Because of cultural reasons, malpractice suits 
and to that extent TDM requirement, is less in 
Eastern societies. The Consumer Protection Act 
in India as applicable to medical care takes 
cognizance of negligence and not ordering a 
drug assay (except probably in a case of sus-
pected toxicity) cannot be construed as negli-
gence by any means. 
Need and recommendations for 
developing countries 
1 TRICYCLIC ANTIDEPRESSANTS 
Only four TCAs have been subjected to 
clinical trials in which blood level measurements 
were made. These are imipramine, amitriptyl-
ine, desmethyl-imipramine and nortriptyline 
(Preskorn et al., 1993). Out of these 
desimipramine is rarely used and for amitriptyl-
ine there is poor co-relation between 
concentration and efficacy in adults. Imipramine 
shows a linear, while nortriptyline shows a 
curvilinear relationship. There are no studies 
which clearly show that TDM driven dose 
adjustments were more effective than clinically 
titrated dose regimes. However there is a case 
for using TDM for TCAs in rare cases of 
particularly intractable patients and for 
detecting suspected toxicity. 
2. SPECIFIC SEROTONIN REUPTAKE IN-
HIBITORS e.g. fluoxetine 
Since they have a flat dose-response 
curve, TDM will not increase effectiveness. 
They have a wide therapeutic margin so toxic-
ity is not a concern. In view of very long half 
life, even compliance check is not possible since 
even noncompliant patients show some 
concentration. As such there is no indication 
for doing TDM of SSRIs in routine practice. 
However an unusual indication is to confirm 
drug washout of fluoxetine before a patient is 
subsequently put on a MAO inhibitor (Preskorn 
etal., 1993). 
107 ANIRUDH K. KALA 
3. TRAZODONE 
TDM with trazodone does not offer any 
advantage (Preskom et al., 1993). No relation-
ship is documented with efficacy. Priapism is 
idiosyncratic. 
4. MAO INHIBITORS 
Conventional TDM is not applicable to 
MAO in view of irreversible inhibition of MAO. 
Some studies have measured platelet MAO 
activity which is much costlier and cumbersome. 
There is need to take two samples. As such 
TDM for MAOI has not been recommended by 
any author. 
5. LITHIUM 
Lithium is the least controversial exam-
ple of TDM. TDM has been widely documented 
as necessary part of standard care with lithium 
treatment and prophylaxis in view of its narrow 
therapeutic index and there is no reason not to 
do it routinely in all patients. However now that 
the profession has about thirty years experience 
with lithium, an important question needs to be 
addressed. The question is that in certain 
community situations where an experienced 
psychiatrist is available, should lithium prophy-
laxis for bipolar affective disorder be withheld? 
Such community situations are fairly common 
in developing countries and it is felt that some 
psychiatrists so placed are already successfully 
making the best of their clinical acumen. In the 
absence of facilities for lithium estimation over 
the last ten years, the author has treated over 
2000, mainly rural, patients from remote areas 
who could not afford routine serum lithium 
estimations for reasons of either cost or 
distance. These patients of recurrent mood 
disorders have been maintained on littiium 
prophylaxis and doses have been adjusted 
clinically. Not a single case of toxicity has been 
seen. However it can be argued that had rou-
tine serum lithium estimation been done, 
prophylaxis of breakthrough episodes would 
have been even more effective. There is a clear 
need to study and report such experiences more 
systematically. 
6.CARBAMAZEPINE AND SODIUM 
VALPROATE 
No reports of TDM are available from 
studies on patients of affective disorder. All the 
reports are from seizure control studies 
(Preskom et al., 1993). Even to assess and 
avoid potential adverse reactions, periodical 
blood counts and liver function tests would be 
more useful and much cheaper. However, TDM 
may be used in some cases of acute car-
bamazepine toxicity. 
7. NEUROLEPTICS 
There are no studies to recommend 
routine use of TDM in patients on neuroleptics. 
Effect is related to both dose and plasma 
levels upto particular limits beyond which 
neuroleptics are not additionally useful and 
cause side effects. Similarly, tardive dyskinesia 
is as much related to dose and duration as to 
plasma levels. TDM may be done for selected 
non-responders, patients who show 
serious unexpected side effects, or to check 
compliance. 
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